Skip to main content

Trileptal

(oxcarbazepine)

Trileptal (oxcarbazepine); not controlled

Full Prescribing Information DailyMed Drug Information

Summary

Trileptal is a sodium channel blocking antiepileptic, supplied as tablets and oral suspension, approved only for partial seizures: monotherapy from 4 years, adjunctive from 2 years. It carries no psychiatric indication at any age, so use for aggression, mood dysregulation or impulse control is entirely off-label. Its defining safety issue is hyponatremia, common enough to require scheduled sodium checks. Not controlled; brand and generic.

Forms & Strengths

  • Tablets: 150 mg, 300 mg, 600 mg
  • Oral suspension: 300 mg/5 mL
  • Extended-release tablets: 150 mg, 300 mg, 600 mg

Dosing

  • Age:
    • Partial seizures, monotherapy: 4 y/o and older
    • Partial seizures, adjunctive: 2 y/o and older
    • Psychiatric and behavioural use: no approved age; entirely off-label
  • Onset: 2 to 4 weeks, the time titration takes to reach target
  • Duration: continuous with twice-daily dosing
  • Initial Dose:
    • Pediatric monotherapy, 4 to 16 y/o: 8 to 10 mg/kg/day in two divided doses
    • Pediatric adjunctive, 2 to 16 y/o: 8 to 10 mg/kg/day divided, generally not above 600 mg/day
    • Under 20 kg: 16 to 20 mg/kg/day may be considered
    • Adults, all uses: 600 mg/day in two divided doses
  • Titration:
    • Pediatric monotherapy initiation: 5 mg/kg/day every 3 days
    • Pediatric conversion to monotherapy: up to 10 mg/kg/day weekly
    • Pediatric adjunctive: reach target over 2 weeks, or 2 to 4 weeks under 4 y/o
    • Adults: up to 600 mg/day weekly; 300 mg/day every third day for monotherapy
  • Max Dose:
    • Pediatric adjunctive, 2 to under 4 y/o: 60 mg/kg/day
    • Adjunctive 4 to 16 y/o: 900 mg/day at 20 to 29 kg, 1200 mg/day at 29.1 to 39 kg, 1800 mg/day above 39 kg
    • Monotherapy maintenance: 600 to 900 mg/day at 20 kg, up to 1500 to 2100 mg/day at 70 kg
    • Adults: 2400 mg/day, which most patients cannot tolerate
  • Considerations: All dosing is twice daily. Halve the starting dose to 300 mg/day and titrate slowly if creatinine clearance is under 30 mL/min; no adjustment for mild to moderate hepatic impairment.

Pharmacology

  • Mechanism: Blocks voltage-gated sodium channels, stabilising hyperexcited membranes; no demonstrated interaction with brain neurotransmitter or modulator receptors
  • Delivery / Release: immediate-release, completely absorbed, median Tmax 4.5 hours; with or without food
  • Metabolism: prodrug converted to the active 10-monohydroxy derivative (MHD); half-life 2 hours parent, 9 hours MHD, 19 hours if creatinine clearance is under 30 mL/min
  • Pharmacogenomics: HLA-B*1502 carriers risk Stevens-Johnson syndrome and toxic epidermal necrolysis. Test before starting in at-risk ancestry; avoid unless benefit clearly outweighs risk.
  • Class Positioning: like carbamazepine but with much less enzyme induction; hyponatremia is more frequent, not less. Adjunct to an ADHD regimen (Concerta, Strattera, Qelbree), never a replacement.

Indications

  • Partial Seizures, monotherapy (ICD-10: G40.1, G40.2): patients 4 y/o and older, and adults
  • Partial Seizures, adjunctive therapy (ICD-10: G40.1, G40.2): patients 2 y/o and older, and adults
  • No other approved indication exists, psychiatric or otherwise, at any age.

Off-Label Uses

  • Aggression, irritability and mood dysregulation (ICD-10: F90.x, F91.x): limited data. Risperidone (Risperdal) has moderate graded evidence here; oxcarbazepine has none. (AHRQ 2017)
  • Where the evidence does not support use:
    • Pediatric bipolar disorder (ICD-10: F31.x): insufficient; the carbamazepine analogy is pharmacological, not evidential.
    • Neuropathic pain, trigeminal neuralgia (ICD-10: G50.0, M79.2): insufficient; no pain indication at any age.
    • Generalized seizures (ICD-10: G40.3): insufficient and potentially harmful; can worsen some generalized epilepsies.

Contraindications & Warnings

  • Class warning, suicidal behaviour and ideation: antiepileptics roughly double the risk (adjusted RR 1.8, 95% CI 1.2 to 2.7), from week one, in every indication.
  • Contraindicated: known hypersensitivity to oxcarbazepine or any component.
  • Use with caution:
    • Prior carbamazepine hypersensitivity: 25% to 30% cross-react. Ask directly.
    • Ancestry in a high HLA-B*1502 frequency population, for Stevens-Johnson syndrome and toxic epidermal necrolysis risk.
    • Any other sodium-lowering drug: thiazides, SNRIs, drugs causing inappropriate ADH secretion.
    • Creatinine clearance under 30 mL/min: halve the starting dose; MHD half-life roughly doubles.
    • Hormonal contraception in an adolescent, because oxcarbazepine reduces its effectiveness.
    • Pregnancy or possible pregnancy, because oxcarbazepine is likely a human teratogen.
  • Screen before starting:
    • Baseline serum sodium; a later result cannot be interpreted without it.
    • Prior reaction to carbamazepine, asked as a direct question.
    • Ancestry, to decide whether HLA-B*1502 testing is indicated first.
    • Renal function; the medication list for sodium-lowering drugs and hormonal contraception.
    • Baseline mood and any history of suicidal ideation.

Drug Interactions

  • Hormonal contraceptives (oral, patch, ring): effectiveness is reduced. Arrange an alternative or added method before the first dose.
  • Other antiepileptics (carbamazepine, phenytoin, phenobarbital): mutual changes in exposure above 1200 mg/day. Check their levels through titration and at any dose change.
  • Calcium antagonists (felodipine, verapamil): exposure is altered. Recheck blood pressure after any change.
  • Other sodium-lowering drugs (thiazides, SSRIs, SNRIs, desmopressin, carbamazepine): additive hyponatremia. Check sodium 2 to 4 weeks after starting and at any dose change.
  • Laboratory tests: T4 falls without T3 or TSH change. Read an isolated low T4 as a drug effect, not hypothyroidism.

Administration

  • Give twice daily at roughly 12-hour intervals. The extended-release oxcarbazepine product is a separate NDA and must not be substituted milligram for milligram.
  • May be taken with or without food.
  • Use the oral suspension for weight-based pediatric dosing rather than splitting tablets.
  • The suspension is 60 mg/mL: divide the milligram dose by 60 for millilitres.
  • Shake the suspension; measure with a calibrated oral syringe, never a kitchen spoon.
  • Do not stop abruptly. See Discontinuation & Taper.

Side Effects

  • Common (at least 5%, above placebo): dizziness, somnolence, diplopia, fatigue, nausea, vomiting, ataxia, abnormal vision, abdominal pain, tremor, dyspepsia, abnormal gait
  • Serious:
    • Hyponatremia: sodium below 125 mmol/L in 2.5% of treated patients, usually asymptomatic. Reduce the dose or stop.
    • Anaphylaxis and angioedema of the larynx, glottis, lips or eyelids: stop and never rechallenge.
    • Stevens-Johnson syndrome and toxic epidermal necrolysis, median onset 19 days. Stop for any rash.
    • DRESS: fever, rash or lymphadenopathy with organ involvement. Discontinue unless another cause is established.
    • Dose-related psychomotor slowing, impaired concentration, speech problems, ataxia and gait disturbance.
    • Pancytopenia, agranulocytosis and leukopenia, rare: consider discontinuation.

Monitoring & Labs

  • Serum sodium: baseline, 2 to 4 weeks after starting, after every dose increase, at 3 months, then at least every 6 months; also 2 to 4 weeks after adding any sodium-lowering drug.
  • Serum sodium, unscheduled: for nausea, malaise, headache, lethargy, confusion, obtundation, or rising seizure frequency. Act before 125 mmol/L.
  • Suicidality and mood: at 1 week, 1 month, every dose change, and each routine visit thereafter.
  • Skin: ask about rash at every visit for the first 3 months; the family reports any rash the same day.
  • Cognitive and motor function: ask family and school about concentration, sleepiness and falls at each dose increase and every 6 months.
  • Contraception review: every visit, in any adolescent who could become pregnant.

Discontinuation & Taper

  • Withdraw gradually, per the label, to minimise increased seizure frequency. This holds even for off-label behavioural use.
  • Converting to another antiepileptic: withdraw over 3 to 6 weeks while the replacement reaches target over 2 to 4 weeks.
  • Stop permanently, no rechallenge, for anaphylaxis, angioedema or any serious dermatological reaction.
  • Discontinue for DRESS unless an alternative cause is established.
  • Reduce or stop for clinically significant hyponatremia; sodium normalises within a few days.
  • Drug holidays are not appropriate for either use.

Pregnancy & Lactation

  • Pregnancy: No adequate controlled studies; the label states oxcarbazepine is likely a human teratogen. Use only if benefit justifies risk.
  • Pregnancy, dosing: plasma MHD falls through pregnancy and returns after delivery; monitor seizure control across pregnancy and postpartum.
  • Lactation: milk-to-plasma ratio 0.5; levels low, adverse effects not expected beyond 2 months. Monitor infant drowsiness, weight gain, milestones. (LactMed 2024)
  • Exposure Registry: North American Antiepileptic Drug Pregnancy Registry, 1-888-233-2334; the patient enrolls herself.

Counseling Points

  • Counsel the family on:

    • This being a seizure medicine; behavioural use is off-label, with no approved dose ladder.
    • The sodium blood test schedule, done even when the child feels well; most affected children have no symptoms.
    • Reporting any rash the same day; name blistering, peeling and mouth or eye sores.
    • Sleepiness, unsteadiness and double vision being dose-related; report after an increase.
    • Never stopping suddenly, even if it seems to be doing nothing: that can trigger seizures.
    • For an adolescent who could become pregnant: less reliable hormonal birth control, likely fetal harm.

  • Advise them to call for:

    • Blistering or peeling skin, or mouth, eye or genital sores, immediately.
    • Swelling of the lips, tongue, eyelids or throat, or trouble breathing.
    • Fever with swollen glands, with or without rash.
    • Headache with unusual sleepiness, confusion, unsteadiness, or more frequent seizures.
    • New or worsening talk of self-harm, or a sudden mood change.
    • Unusual bruising, bleeding, or repeated infections.

References

  1. DailyMed. Trileptal (oxcarbazepine) tablets prescribing information. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33af9350-95f3-384e-e054-00144ff88e88
  2. LactMed. Oxcarbazepine. Drugs and Lactation Database, National Institute of Child Health and Human Development. 2024. https://www.ncbi.nlm.nih.gov/books/NBK501243/
  3. AHRQ. First- and second-generation antipsychotics in children and young adults: systematic review update. Comparative Effectiveness Review No. 184. 2017. https://www.ncbi.nlm.nih.gov/books/NBK442344/
  4. FDA. National Drug Code Directory, openFDA. Queried by generic name oxcarbazepine. 2026. https://api.fda.gov/drug/ndc.json?search=generic_name:%22oxcarbazepine%22&limit=1000
Back to top